All News

SEER and Medicare data project rising DLBCL and MCL cases through 2032, intensifying payer strain and demand for Brukinsa, Calquence, and CAR-T access.

ASCO real-world oncology data show racial disparities in pain management, with delayed meds and fewer strong opioids for Black and Asian patients.

Deloitte's midyear analysis shows internal confidence rising even as external uncertainty over policy, tariffs, and reimbursement persists for biopharma and medtech.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

Interviews with patients living with generalized myasthenia gravis (MG) in the US revealed areas of increased burden in these patients.

A Medicare claims analysis found zanubrutinib was associated with significantly longer treatment duration and overall survival vs acalabrutinib and ibrutinib.

The move follows the close of a 42-day quarantine for American cruise-ship passengers exposed to the rare Andes strain.

Asthma biologics were associated with sustained reductions in exacerbations after 2015 across demographic and clinical subgroups in a large cohort study.

A study found significant drops in mean platelet volume and rises in platelet count after 6 months of SGLT2 inhibitor therapy, independent of diuretic use.

Bhavana “Tina” Bhatnagar, DO, reflects on AML’s transformation from few treatment options to targeted therapies and efforts to increase access to them.

Children of mothers with poor cardiovascular health during pregnancy had nearly double the risk of developmental delay at age 4.

The phase 3 SigVie-002 trial showed sigvotatug vedotin missed the OS end point, but the second-line subgroup showed a survival trend and manageable safety.

FDA approval of generic rifapentine introduces a new option for treating active tuberculosis and preventing progression of latent infection.

Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.

Structured CHE diagnosis improves outcomes: a multicenter CRF clarifies causes for most patients with chronic hand eczema, addressing diagnosis challenges and guiding targeted care.

Adults with obesity using an AI-CGM platform lost weight nearly 3 times faster during engaged vs nonengaged periods (1.17% vs 0.44% per week).

Real-world data show AI coaching plus CGM helps adults with obesity lose up to 7% in 6 months, with engagement driving faster weekly weight loss.

EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.

Patients with early relapsing multiple sclerosis (MS) were able to switch to ocrelizumab after suboptimal responses to other disease-modifying therapies.

New formulations make topical retinoids for acne vulgaris and scarring more tolerable and effective, with promising data for trifarotene, tretinoin combinations, and retinols for acne.

The 2 risks operate independently so that social interventions can reduce disease risk regardless of a patient’s genetic profile.

The 2026 conference, held in Baltimore, Maryland, offered expert insight into the past and future of sleep medicine.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

Canadian dermatologists propose treat-to-target benchmarks for chronic hand eczema, pairing IGA-CHE and itch scores to guide therapy and follow-up.

Creatinine, not just a diabetes diagnosis, should trigger SGLT2 inhibitor use in CKD, says Sandra Chaparro, MD.

Resistance training, especially when paired with aerobic activity and limited TV time, was associated with the steepest reductions in type 2 diabetes risk.

Sheng Fu, MD, says the biggest barriers to managing heart failure, CKD, and obesity together aren't new drugs—they're broken transitions of care.

The FDA issued a CRL for cytisinicline's NDA over manufacturing deficiencies at a third-party facility, with no efficacy or safety concerns cited.